Exact Sciences Corp
NASDAQ:EXAS
Exact Sciences Corp
Total Receivables
Exact Sciences Corp
Total Receivables Peer Comparison
Competitive Total Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Exact Sciences Corp
NASDAQ:EXAS
|
Total Receivables
$240.6m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$11.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
16%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
4%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$6.8B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
10%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$1.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
33%
|
CAGR 10-Years
40%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$5.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
18%
|
CAGR 10-Years
17%
|
See Also
What is Exact Sciences Corp's Total Receivables?
Total Receivables
240.6m
USD
Based on the financial report for Mar 31, 2024, Exact Sciences Corp's Total Receivables amounts to 240.6m USD.
What is Exact Sciences Corp's Total Receivables growth rate?
Total Receivables CAGR 5Y
34%
Over the last year, the Total Receivables growth was 31%. The average annual Total Receivables growth rates for Exact Sciences Corp have been -2% over the past three years , 34% over the past five years .